x

Member Login

TRIUMPH

Tofacitinib for hospitalized acute severe Ulcerative colitis Management (the TRIUMPH study)

 

PIs: Dr. Neeraj Narula, McMaster University & Dr. Tawnya Hansen, University of Manitoba

 

Co-Investigators

Dr. Brian Bressler, University of British Columbia

Dr. Talat Bessissow, McGill University

Dr. Farhad Peerani, University of Alberta

 

Purpose

The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in a subset of ulcerative colitis patients. We are looking to determine if there is benefit from tofacitinib in the severe hospitalized population.

 

Study Design

To determine the effectiveness (combined and endoscopic response) and safety of tofacitinib  in patients with acute severe UC who experience treatment failure to steroids or anti-TNFα/anti-integrin therapies/anti-interleukin therapies. The primary outcome of this study is to assess clinical response at day 7 among patients who receive tofacitinib.

 

Participating Sites

Hamilton Health Sciences Centre/McMaster University

University of Manitoba

McGill University

University of British Colombia

University of Alberta

 

For more information on Inclusion & Exclusion Criteriaclick here.

 

Targets

Anticipated sample size: 26
Anticipated start date: April 2021
Anticipated end: October 2022

Additional sites are welcome! Please contact Dr. Neeraj Narula (neeraj.narula@medportal.ca) or Dr. Tawnya Hansen at (hansen.tawnya@gmail.com) for more information.